GlaxoSmithKline (GSK -2.67%), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can Glaxo Show Its Worth in 2013?
By Max Macaluso
–
Jan 19, 2013 at 6:00PM
NYSE: GSK
GSK
Market Cap
$81B
Today's Change
(-2.67%) -$1.06
Current Price
$38.66
Price as of June 18, 2025, 3:58 p.m. ET
Is GlaxoSmithKiline's revolutionary R&D strategy going to work?
David Williamson, Max Macaluso, Ph.D., and The Motley Fool has no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
GSK
GSK
$38.66
(-2.67%)
$-1.06
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
Is GSK a Top Value Stock Right Now?
Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors?
Is GSK Stock Worth Buying Right Now?
Is GSK a Strong Buy Right Now?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.